Interferon: History, Correlation, Mechanism, and limitation

Authors

  • Qilin Liu

DOI:

https://doi.org/10.62051/s18vd181

Keywords:

Interferon; cancer; cytokines.

Abstract

Nowadays, more and more patients suffer from cancer in clinical practice, which has become a hot topic in medical care. The researchers are struggling to find new cancer therapy. Cytokines are a group of protein molecules, and Interferon is the class of them. It has regulation and adjusting ability in the immune system. Moreover, in cancer research, it occupies a momentous role in its ability to combine with other drugs and special effects. Interferon was first found in the 20th century and is widely used in Melanoma, chronic myelogenous leukemia, and hepatocellular carcinoma therapy. In simple terms, Interferon possesses anti-tumor effects by regulating NK cells and T cells. It enhances antigen presentation and supervises the immune system. Additionally, it inhibits tumor angiogenesis, triggers apoptosis and necrosis, and alters the tumor micro-environment. However, Interferon isn’t denying that having some limitations like side effects, potential risk, bottlenecks and high costs. These may cause patients to get injured. To discuss these aspects, the essay will be based on the research made before and summarize them to get conclusions. Besides, it also uses comparison to argue the issues. The research has shown that although Interferon has different functions and a long period of research, it is still in active research to find new contributions now, and patients may use the new drug or therapy one day to Interferon’s ramifications.

Downloads

Download data is not yet available.

References

[1] Isaacs Alick and Lindenmann J.1957Virus interference. I. The interferonProc. R. Soc. Lond. B147258–267.

[2] MARCO DE ANDREA, RAFFAELLA RAVERA, DANIELA GIOIA, MARISA GARIGLIO, SANTO LANDOLFO, The interferon system: an overview,European Journal of PaediatricNeurology, Volume 6, Supplement A, 2002, Pages A41-A46, ISSN 1090-3798.

[3] Alfons Billiau, Patrick Matthys, Interferon-γ: A historical perspective, Cytokine & Growth Factor Reviews, Volume 20, Issue 2, 2009, Pages 97-113, ISSN 1359-6101.

[4] Diana L Brassard, Michael J Grace, Ronald W Bordens, Interferon-α as an immunotherapeutic protein, Journal of Leukocyte Biology, Volume 71, Issue 4, April 2002, Pages 565–581.

[5] Martina Sanlorenzo, Igor Vujic, Fabrizio Carnevale-Schianca, Pietro Quaglino, Loretta γitoni, Maria Teresa Fierro, Massimo Aglietta & Dario Sangiolo (2017) Role of interferon in melanoma: old hopes and new perspectives, Expert Opinion on Biological Therapy, 17: 4, 475-483.

[6] M. Raza Zaidi, Interferon-γ Paradox in Cancer, Journal of Interferon & Cytokine Research 2019 39: 1, 30-38.

[7] Brok, J., Gluud, L. L., & Gluud, C. (2005). Effects of adding ribavirin to interferon to treat chronic hepatitis C infection: a systematic review and meta-analysis of randomized trials. Archives of Internal Medicine 165, 2206–2212.

[8] Eric Jonasch, Frank G. Haluska, Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities, The Oncologist, Volume 6, Issue 1, February 2001, Pages 34–55.

[9] Crott, R. Cost Effectiveness and Cost Utility of Adjuvant Interferon α in Cutaneous Melanoma. PharmacoEconomics 22, 569–580 (2004).

[10] Jorgovanovic, D., Song, M., Wang, L. et al. Roles of IFN-γ in tumor progression and regression: a review. Biomark Res 8, 49 (2020).

[11] Mojic, M.; Takeda, K.; Hayakawa, Y. The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion. Int. J. Mol. Sci. 2018, 19, 89.

[12] Reiko E Yamada et al. Anti-CD20-interferon-α fusion protein has superior in vivo activity against human B-cell lymphomas compared to rituximab and enhanced complement-dependent cytotoxicity in vitro.. JCO 31, 3024-3024 (2013).

Downloads

Published

10-10-2024

How to Cite

Liu, Q. (2024). Interferon: History, Correlation, Mechanism, and limitation. Transactions on Materials, Biotechnology and Life Sciences, 5, 8-13. https://doi.org/10.62051/s18vd181